Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27632212 | 0.83 | MIF (0.55) | HDAC4HDAC8THRATHRBFYN | |
| SCHEMBL14832084 | 0.83 | RPS6KA3 (0.55) | HDAC4HDAC8FYNRPS6KA3CYP1A2 | |
| SCHEMBL10094666 | 0.82 | ABL1 (0.51) | RPS6KA3ALOX15CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18087561 | 0.82 | ACHE (0.53) | HDAC4HDAC8THRATHRBFYN | |
| SCHEMBL4970056 | 0.82 | CYP1A2 (0.53) | HDAC4HDAC8FYNALOX15CYP1A2 | |
| SCHEMBL16428977 | 0.81 | ESR2 (0.53) | THRBFYNALOX15MEN1NPC1 | |
| SCHEMBL6572257 | 0.81 | FYN (0.55) | HDAC4HDAC8THRATHRBFYN | |
| SCHEMBL10014739 | 0.80 | AKR1C3 (0.58) | RPS6KA3ALOX15NPC1RAB9ACYP1A2 | |
| SCHEMBL3362978 | 0.80 | HDAC4 (0.62) | HDAC4HDAC8MEN1USP2KMT2A | |
| Hydrochloric Acid SCHEMBL6781218 | 0.79 | FYN (0.54) | HDAC4HDAC8THRATHRBFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9586963-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2017-03-07 | — | — | US | disclosed |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | NR1D1, NR1D2, PER2 | HDAC4 515/4885HDAC8 1205/4885THRA 58/4885 |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | HDAC4 515/4885HDAC8 1205/4885THRA 58/4885 |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | HDAC4 515/4885HDAC8 1205/4885THRA 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.